HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yu Li Selected Research

Macrophage Inflammatory Proteins (Macrophage Inflammatory Protein 1)

10/2018The N-terminal polypeptide derived from vMIP-II exerts its anti-tumor activity in human breast cancer by regulating lncRNA SPRY4-IT1.
6/2017The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.
4/2017N-terminal polypeptide derived from vMIP-II exerts its antitumor activity by inhibiting the CXCR4 pathway in human glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yu Li Research Topics

Disease

291Neoplasms (Cancer)
08/2022 - 06/2002
74Inflammation (Inflammations)
11/2022 - 10/2009
63Neoplasm Metastasis (Metastasis)
01/2022 - 06/2002
58Infections
06/2022 - 09/2002
44Insulin Resistance
07/2022 - 10/2004
43Breast Neoplasms (Breast Cancer)
12/2021 - 11/2002
41Hepatocellular Carcinoma (Hepatoma)
10/2021 - 08/2002
36Obesity
07/2022 - 10/2004
29Lung Neoplasms (Lung Cancer)
07/2022 - 11/2003
27Fibrosis (Cirrhosis)
07/2022 - 02/2007
27Hypoxia (Hypoxemia)
01/2022 - 05/2009
26Adenocarcinoma of Lung
01/2022 - 06/2002
25Alzheimer Disease (Alzheimer's Disease)
03/2022 - 02/2006
21Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 07/2005
21Carcinogenesis
08/2020 - 02/2004
19Atherosclerosis
02/2021 - 04/2011
17Osteoporosis
09/2022 - 03/2013
17COVID-19
03/2022 - 01/2020
17Type 2 Diabetes Mellitus (MODY)
03/2022 - 04/2011
17Body Weight (Weight, Body)
01/2022 - 02/2006
17Ischemia
01/2021 - 11/2010
16Adenocarcinoma
07/2022 - 12/2015
16Fatty Liver
01/2022 - 01/2013
15Glioma (Gliomas)
07/2022 - 01/2012
15Non-alcoholic Fatty Liver Disease
03/2022 - 01/2014
15Pain (Aches)
01/2022 - 02/2005
14Colonic Neoplasms (Colon Cancer)
01/2022 - 01/2004
14Carcinoma (Carcinomatosis)
11/2019 - 06/2002
13Prostatic Neoplasms (Prostate Cancer)
06/2022 - 11/2011
13Reperfusion Injury
01/2021 - 11/2010
13Stomach Neoplasms (Stomach Cancer)
01/2021 - 12/2008
12Hypersensitivity (Allergy)
01/2022 - 05/2014
12Pneumonia (Pneumonitis)
08/2021 - 10/2013
12Hypertension (High Blood Pressure)
07/2021 - 01/2014
11Cognitive Dysfunction
12/2021 - 07/2012
11Chronic Obstructive Pulmonary Disease (COPD)
12/2021 - 12/2008
11Brain Injuries (Brain Injury)
12/2021 - 01/2012
10Liver Cirrhosis (Hepatic Cirrhosis)
07/2022 - 11/2005
10Wounds and Injuries (Trauma)
10/2020 - 09/2011
9Smallpox (Variola)
04/2022 - 07/2006
9Liver Neoplasms (Liver Cancer)
03/2022 - 10/2015
9Asthma (Bronchial Asthma)
11/2021 - 01/2003
9Colorectal Neoplasms (Colorectal Cancer)
03/2021 - 05/2004
9Necrosis
01/2021 - 08/2006
9Lymphatic Metastasis
02/2019 - 02/2004
8Spinal Cord Injuries (Spinal Cord Injury)
12/2022 - 08/2015
8Hemorrhage
06/2022 - 10/2009
8Metabolic Syndrome (Dysmetabolic Syndrome X)
04/2022 - 12/2018
8Liver Diseases (Liver Disease)
03/2022 - 09/2002
8Osteosarcoma (Osteogenic Sarcoma)
01/2022 - 01/2013
8Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 03/2007

Drug/Important Bio-Agent (IBA)

116Proteins (Proteins, Gene)FDA Link
11/2022 - 06/2003
57Pharmaceutical PreparationsIBA
02/2022 - 02/2007
55Biomarkers (Surrogate Marker)IBA
08/2022 - 10/2008
47Messenger RNA (mRNA)IBA
07/2022 - 06/2003
46MicroRNAs (MicroRNA)IBA
05/2022 - 08/2009
43Glucose (Dextrose)FDA LinkGeneric
07/2022 - 10/2007
39LipidsIBA
07/2022 - 04/2011
36Biological ProductsIBA
07/2022 - 06/2002
30Therapeutic UsesIBA
08/2022 - 07/2004
25VaccinesIBA
04/2022 - 05/2006
22Long Noncoding RNAIBA
06/2022 - 02/2015
21DNA (Deoxyribonucleic Acid)IBA
04/2022 - 09/2002
21Insulin (Novolin)FDA Link
03/2022 - 10/2004
21Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 07/2005
21AntigensIBA
01/2021 - 07/2002
18Peptides (Polypeptides)IBA
09/2022 - 03/2003
18CytokinesIBA
09/2021 - 04/2010
15Anti-Bacterial Agents (Antibiotics)IBA
01/2022 - 12/2010
15AntibodiesIBA
01/2022 - 05/2006
15Interleukin-6 (Interleukin 6)IBA
01/2021 - 01/2013
14Small Interfering RNA (siRNA)IBA
03/2022 - 05/2012
14EnzymesIBA
01/2022 - 01/2011
14CurcuminIBA
01/2022 - 04/2011
13AntioxidantsIBA
11/2022 - 11/2015
13RNA (Ribonucleic Acid)IBA
08/2022 - 01/2018
13CholesterolIBA
12/2021 - 01/2013
12Blood Glucose (Blood Sugar)IBA
01/2022 - 10/2009
12Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2021 - 04/2010
11Oxygen (Dioxygen)IBA
01/2022 - 03/2014
11CateninsIBA
01/2021 - 04/2011
11Fatty Acids (Saturated Fatty Acids)IBA
01/2020 - 10/2009
10Reactive Oxygen Species (Oxygen Radicals)IBA
05/2022 - 07/2014
10CalciumIBA
02/2022 - 02/2013
10Transcription Factors (Transcription Factor)IBA
01/2022 - 09/2012
10Amyloid (Amyloid Fibrils)IBA
11/2021 - 08/2003
10LipopolysaccharidesIBA
08/2021 - 06/2007
10Matrix Metalloproteinases (MMPs)IBA
01/2021 - 04/2006
10Caspase 3 (Caspase-3)IBA
01/2021 - 09/2013
9Polysaccharides (Glycans)IBA
01/2022 - 10/2008
9LigandsIBA
11/2021 - 06/2016
9Protein Kinases (Protein Kinase)IBA
01/2021 - 10/2004
8AcidsIBA
07/2022 - 10/2007
8Antiviral Agents (Antivirals)IBA
04/2022 - 10/2012
8Sirtuin 1IBA
01/2022 - 05/2011

Therapy/Procedure

119Therapeutics
12/2022 - 01/2004
28Drug Therapy (Chemotherapy)
07/2022 - 02/2005
20Immunotherapy
01/2022 - 10/2003
18Chinese Traditional Medicine (Traditional Chinese Medicine)
01/2022 - 05/2014
10Stents
11/2021 - 03/2007